Michelson has raised ,during October 2018, circa £0.645 million of a two stage fundraise of £1.4 million. The second stage of fund raising will commence in May 2019 once Sciton and Michelson have completed substantially both the clinical trial and the business evaluation programmes needed before the OCT guided laser skin treatment applications are launched in the USA.

Sciton and Michelson are combining Michelson's OCT VivoSight diagnostic scanner with Sciton's range of aesthetic laser treatment laser modules to treat more effectively a range of skin disorders. The first four applications are:

 

  • OCT guided laser treatment of BCC - a very common non melanoma skin cancer
  • OCT guided laser treatment of difficult to treat vascular lesions.
  • OCT guided laser treatment of striae
  • OCT guided laser treatment of surgical scars
  •